Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia

• Main Authors: Chenglin Wu (Author), Cong Xi (Author), Junhua Tong (Author), Jing Zhao (Author), Hualiang Jiang (Author), Jiang Wang (Author), Yiping Wang (Author), Hong Liu (Author)
• Format: Book
• Published: Elsevier, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators may attenuate PCSK9-induced low-density lipoprotein receptor (LDLR) degradation in lysosome and promote the clearance of circulating low-density lipoprotein cholesterol (LDL-C). A novel series of tetrahydroprotoberberine derivatives (T...